Ebb & Flow

Adventrx Pharmaceuticals Inc. (NYSE-A:ANX) fell $0.09 (30%) to $0.20 on Monday after FDA refused to file an NDA for ANX-530 to treat non-small cell lung cancer (NSCLC) because of a problem with CMC data from the intended commercial manufacturing site. The stock was off $0.07 (24%) to $0.22 for the week.

Amgen Inc. (NASDAQ:AMGN) gained $0.63 to $57.24 last week after the U.K.'s NICE issued a preliminary appraisal for five drugs to treat rheumatoid arthritis after failure on a TNF inhibitor. NICE reiterated recommendations in favor of MabThera rituximab, a mAb against CD20 from Roche (SIX:ROG; OTCQX:RHHBY); and against use of Orencia abatacept, a CTLA-4-Ig fusion protein from Bristol-Myers Squibb Co. (NYSE:BMY)...